Qalsody is one step closer to being covered by public Canadian healthcare systems when used to treat adults with ALS with ...

Today, after receiving a gene therapy developed at the University of California San Diego, Natalie is thriving at 34 years ...

The Australian research, which aims to help people with motor neuron disease keep moving, is now testing AI to personalise assistance.

An A.I.-powered avatar platform aims to restore speech, identity and dignity for people living with ALS and paralysis.

More than 250 community members gathered Saturday morning at Miller/Knox Regional Shoreline in Richmond for the 26th Annual ...

In 2025, Hollywood star Eric Dane shared with the world that he had been diagnosed with a serious disorder that has left him ...

Japan’s Tanabe Pharma, formerly known as Mitsubishi Tanabe and now owned by Bain Capital, has obtained approval from the ...

FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen’s UPLIZNA ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...

EXCLUSIVE: Big Sky alumna Jamie-Lynn Sigler is returning to ABC with a guest-starring role on the network’s hit medical drama ...

In addition to ALS, pridopidine is in late-stage clinical development for HD, with Prilenia and Ferrer planning to initiate a confirmatory study in HD designed to confirm pridopidine's effects and ...